Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?

• Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
• Discussing dual-target and multispecific approaches
• Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC

Speakers:

John Flygare

Head of Large Molecule & ADC Innovation

Eli Lilly & Co.

David Poon

Head of Corporate Development

DCx Bio

Ugur Eskiocak

Chief Executive Officer & Co-Founder

Voro Therapeutics

Jing Li

Founder & Chief Executive Officer

VelaVigo

Arne Scheu

Co-Founder & Chief Executive Officer

Valink Therapeutics

Paul Moore

Chief Scientific Officer

Zymeworks